Last update July 5, 2022
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Эсциталопрама Оксалат is Escitalopram Oxalate in Cyrillic.
Is written in other languages:Эсциталопрама Оксалат is also known as
Эсциталопрама Оксалат belongs to these groups or families:
Main tradenames from several countries containing Эсциталопрама Оксалат in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
SSRI antidepressant with actions and uses similar to those of fluoxetine. S-Enantiomer of Citalopram that shares similar pharmacokinetics with Citalopram Oral administration once daily.
It is excreted in breast milk in small amounts (Weisskopf 2020 y 2017, Delaney 2018, Hackett 2006, Rampono 2006, Castberg 2006) .
Serum levels of infants from breastfeeding mothers who were treated have been shown to be undetectable or very low. (Delaney 2018, Rampono 2006)
Overall, short or long-term harmful effect has not been reported among breastfed infants (Hackett 2006, Gentile 2006, Rampono 2006, Castberg 2006). Isolated cases of irritability, sleepiness (Kronenfeld 2018), neonatal necrotizing enterocolitis (Potts 2007) or convulsión (Neuman 2014) after intrauterine exposure and/or polytherapy have appeared in medical literature contrasting with harmlessness reported by others.
Galactorrhea, associated or not to hyperprolactinemia, may appear. (McGrane 2019, Pathania 2018, Suthar 2018, Kaba 2017, Shim 2009, Gulsun 2007)
Several medical societies, experts and expert consensus, consider the use of this medication safe or probably safe during breastfeeding. (Hale, Lactmed, Uguz 2021, Weisskopf 2020, Davanzo 2014 y 2011, Rowe 2013, Bellantuono 2013 y 2012, Berle 2011, Amir 2011)
Safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity. (Orsolini 2015, Sriraman 2015, Patil 2011)
Women suffering from depression during pregnancy need more breastfeeding support due to their increased risk of breastfeeding problems and early weaning. (Grzeskowiak 2018, Leggett 2017, Gorman 2012)
See below the information of this related product: